All articles by Drug Target Review – Page 38
-
NewsCancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
-
NewsEssential insights into HIV-1 latency mechanisms
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
-
NewsNew ENaC blocker demonstrates an extended duration of action
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
-
NewsWerner syndrome: mechanism behind atherosclerosis elucidated
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
-
ReportBeyond the lab: screening
This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cancer and metabolic disease, with expert insights from leading professionals in the field.
-
NewsEpigenetic dysregulation mechanism in Crohn’s disease discovered
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
-
NewsIdentification of functional sex differences in nociceptors
A new study reveals that pain management could be greatly improved by considering patient sex as fundamental.
-
NewsP. aeruginosa infection method elucidated with microtissue model
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
-
NewsNew silk-based membrane for organ-on-a-chip platform
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
NewsNew biological pathway in IBD discovered
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
-
NewsMitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
-
News
Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
-
NewsProteogenomics: finding targets for never-smoker lung cancer
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
-
NewsNovel version of CRISPR gene-editing protein engineered
Researchers have developed a new, compact EbCas12a variant that can be packaged into an all-in-one AAV system with its crRNA.
-
NewsTargeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
-
ArticleExploring the wonders of molecular biology
In this episode, we explore our understanding of DNA and its implications for health outcomes. Additionally, we discuss the transition from DNA sequencing to actionable insights in medicine, contrasting genetics-driven drug discovery with traditional methods. Finally, we examine the evolving landscape of genetic technology and its potential impact on the ...
-
NewsNew method to predict effectiveness of MSCs for cartilage repair in vitro
Topological defects in mesenchymal stromal cell self-assembly could suggest their potential for cartilage regeneration.
-
NewsThe therapeutic potential of targeting guidance receptors
Researchers found that relaxing glial spacing by targeting Plexin-B1 has great therapeutic potential for Alzheimer’s disease.
-
NewsReprogramming immune-suppressive macrophages in tumours
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.